Moderna has completed registration in phase 2/3 of its Corona virus vaccine for adolescents between the ages of 12 and 17, the company said that it has completed the registration of "3000 participants", and the company previously expected that it will achieve results before the next academic year, according to what was published by Fox News American.
The two-dose vaccine also received emergency clearance in December for individuals 18 years of age or older. The Pfizer-Bionic vaccine, which is also a two-dose dose, was approved weeks before for use in individuals 16 years of age and older. Johnson & Johnson submitted a request. EUA to use a single shot vaccine for individuals 18 years of age and older, pending a decision.
Moderna CEO Stephan Bancel said he believes the data on children under the age of 11 will not be available until 2022, the company must first look at the data from trials involving people between the ages of 12 and 17 before it can adjust it. To suit the younger population.
Combating vaccine frequency among US adults has been a focal point in launching the nation, with many questioning the development timeline versus the usual years-long process. Senior officials, such as Dr. Anthony Fauci, the nation's leading infectious disease expert, have repeatedly said that technological advances and federal funding have made this possible.
On the one hand, the American Academy of Pediatrics said in its interim guidelines for vaccination against Corona virus: “Vaccines are essential and safe mechanisms that protect individuals and populations from infectious diseases, based on existing science. Many vaccines have been developed against the Coronavirus, the virus that causes Corona, and are now in Clinical trials.
Comments
Post a Comment